ARTICLE | Clinical News

Genentech regulatory update

November 1, 1993 8:00 AM UTC

CRI occurs in children with irreversible kidney damage. The condition affects 3,000 children in the U.S. and Nutropin has orphan drug designation.

Data presented to the advisory panel were from ongoing Phase III trials in 195 patients. Height in the normal range was achieved in 40 of 62 patients (65 percent) treated for two years, and 29 of 32 patients (91 percent) treated for an average of 3.7 years. ...